Autoimmune Diseases  >>  Orencia (abatacept)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

15 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Orencia (abatacept) / BMS
NCT00119678 / 2004-004051-19: Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone

Checkmark Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus
Oct 2015 - Oct 2015: Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus
Completed
2b
183
US, Canada, Europe, RoW
Abatacept, Orencia, Placebo, Prednisone
Bristol-Myers Squibb
Systemic Lupus Erythematosus
11/08
11/08
NCT00162266: Abatacept With Methotrexate- Phase IIB

Completed
2b
524
US, Canada, Europe, RoW
Abatacept (BMS-188667), Placebo
Bristol-Myers Squibb
Rheumatoid Arthritis
09/09
09/09
NCT00035529: A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis

Terminated
2
US
Placebo, BMS 188667 (Abatacept), Orencia
Bristol-Myers Squibb
Multiple Sclerosis
12/03
12/03
NCT00162279: The Study of Abatacept in Combination With Etanercept

Completed
2
141
US
Abatacept
Bristol-Myers Squibb
Rheumatoid Arthritis
02/07
02/07
NCT00124449 / 2004-002620-18: Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis (RA) in Adult Patients

Completed
2
56
US, Europe, RoW
Abatacept, Orencia, placebo
Bristol-Myers Squibb
Arthritis, Rheumatoid
05/07
04/08
NCT00345748: A Study of Abatacept in Japanese Patients With Active Rheumatoid Arthritis While Receiving Methotrexate

Checkmark P2 data
Jun 2012 - Jun 2012: P2 data
Completed
2
194
Japan
Abatacept, Orencia, Placebo
Bristol-Myers Squibb
Rheumatoid Arthritis
11/07
11/07
ABAVAS, NCT00482066 / 2006-001859-35: Abatacept in ANCA Associated Vasculitis

Terminated
2
7
Europe
Abatacept (Orencia)
Imperial College London, Bristol-Myers Squibb
ANCA-associated Vasculitis
11/08
11/08
ACCESS, NCT00774852: Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis

Checkmark
Aug 2014 - Aug 2014: 
Checkmark ACR/ARHP 2013
Sep 2013 - Sep 2013: ACR/ARHP 2013
Completed
2
137
US, RoW
abatacept, CTLA4Ig, Orencia, cyclophosphamide, Cytoxan, Neosar, azathioprine, Imuran, Azasan, prednisone, Sterapred, abatacept placebo, azathioprine placebo
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN)
Lupus Nephritis, Lupus Erythematosus, Systemic
12/12
06/14
ACCLAIM, NCT01116427: A Cooperative Clinical Study of Abatacept in Multiple Sclerosis

Completed
2
65
US, Canada
abatacept, Orencia®, CTLA4-Ig, Placebo, placebo abatacept
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN)
Multiple Sclerosis, Relapsing-Remitting
06/14
02/15
NCT02027298: Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study

Withdrawn
2
0
US
Abatacept, Orencia
The Cleveland Clinic, Bristol-Myers Squibb
Primary Sjogren's Syndrome, Secondary Sjogren's Syndrome, Inflammatory Arthritis, Rheumatoid Arthritis
10/14
10/14
NCT00276250: Islet Transplantation Using Abatacept

Completed
2
5
US
Efalizumab, Raptiva, Abatacept, Orencia, Belatacept, Nulojix
Emory University, Juvenile Diabetes Research Foundation
Type 1 Diabetes Mellitus
12/14
12/14
NCT00556439: Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis

Completed
2
97
US, Canada
Abatacept, Orencia, Placebo
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), The Cleveland Clinic, Office of Rare Diseases (ORD), Rare Diseases Clinical Research Network
Takayasu's Arteritis, Giant Cell Arteritis
08/15
08/15
NCT00279760: Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis

Completed
1/2
210
US, Canada, Europe
Belatacept, Abatacept
Bristol-Myers Squibb
Rheumatoid Arthritis
03/02
 
NCT00254293: Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)

Completed
1/2
87
US
Abatacept or Placebo (both as IV & SC Solution), Orencia, Abatacept or Placebo (both as IV & SC solution), Abatacept
Bristol-Myers Squibb
Rheumatoid Arthritis
05/07
07/12
NCT00468208: Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis

Checkmark
Dec 2013 - Dec 2013: 
Completed
1/2
20
US
Abatacept
University of Pennsylvania, Office of Rare Diseases (ORD), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Rare Diseases Clinical Research Network
Wegener's Granulomatosis
08/11
08/11

Download Options